Core Viewpoint - Baize Medical Group Limited has successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 560 million through the issuance of 133 million shares at a price of HKD 4.22 per share [1][3]. Group 1: Listing Details - On its first trading day, Baize Medical opened at HKD 5.25 per share, a 24.41% increase from the IPO price, and closed at HKD 6.00 per share, representing a 42.18% increase [3]. - The public offering was oversubscribed by 25.92 times, while the international offering was subscribed at 0.98 times [3]. - A cornerstone investor, Harvest Oriental, invested USD 19 million in the company's shares [3]. Group 2: Company Overview - Established in July 2017, Baize Medical primarily engages in investment and provision of medical services, focusing on oncology [5]. - The company operates and manages eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces, including six for-profit and two non-profit hospitals [5]. Group 3: Financial Performance - Revenue for Baize Medical was approximately RMB 802.65 million in 2022, RMB 1.07 billion in 2023, and is projected to reach RMB 1.19 billion in 2024 [6]. - Adjusted net profit was reported as RMB -75.34 million in 2022, RMB -9.62 million in 2023, and is expected to be RMB 12.50 million in 2024 [7]. - Adjusted EBITDA figures were RMB 35.14 million in 2022, RMB 107.51 million in 2023, and projected at RMB 119.55 million in 2024 [7].

来源|贝多财经 6月13日，佰泽医疗集团有限公司（下称"佰泽医疗"，HK:02609）披露发售公告，于6月13日至6月18日招股，拟全球发售1.33亿股，预计将于2025年6月23日 在港交所上市。 据招股书介绍，佰泽医疗是一家主要从事投资及提供医疗相关服务的肿瘤医疗集团。目前，该公司通过6家民营营利性医院的直接股权所有权、2家民营非营 利性医院的管理权，在北京、天津、山西省、安徽省、河南省运营和管理8家医院。 其中，6家民营营利性医院指的是北京京西肿瘤医院、天津石氏医院、天津南开济兴医院、太原和平医院、合肥佰惠长荣医院、武陟济民医院，2家民营非营 利性医院则为黄山首康医院、太原市万柏林区和平小区卫生服务中心。 佰泽医疗在招股书中称，该公司专注于开展肿瘤相关医疗服务，包括但不限于对患者开展肿瘤诊断、多种手段的肿瘤治疗、肿瘤康复及临终关怀等，以及对 包括肿瘤患者家属在内的其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。 自2023年3月起，太原和平医院由二级甲等综合医院升级为三级康复专科医院，成为山西省首家三级康复专科医院；自2024年4月起，武陟济民医院由二级甲 等综合医院升级为三级综合医院，成为 ...